CIPLA

P/E Ratio: 23x P/B Ratio: 3.8x; Dividend Yield: around 0.9–1.1% Financial Health: Low debt, healthy ROCE 22.7%, ROE ~17.8%, consistent profit growth (29.5% CAGR over past 5 years) Cipla appears well-positioned with robust profitability, a healthy balance sheet, and favorable analyst sentiment. If you're bullish on Indian pharma income growth and new approvals, this could be a solid addition. However, if you’re cautious about valuation and near-term risks, waiting for a dip closer to ₹1,400–₹1,500 might offer a better entry point.